NASDAQ:CRSP - Crispr Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Crispr Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $53.45 +4.01 (+8.11 %) (As of 02/28/2020 04:00 PM ET) Add Compare Today's Range$47.00Now: $53.45▼$53.5050-Day Range$49.44MA: $55.40▼$59.9052-Week Range$33.55Now: $53.45▼$74.00Volume1.64 million shsAverage Volume1.14 million shsMarket Capitalization$3.25 billionP/E Ratio55.10Dividend YieldN/ABeta3.25 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP Previous Symbol CUSIPN/A CIK1674416 Webhttp://www.crisprtx.com/ Phone41-41-561-3277Debt Debt-to-Equity RatioN/A Current Ratio17.29 Quick Ratio17.29Price-To-Earnings Trailing P/E Ratio55.10 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$289.59 million Price / Sales11.23 Cash Flow$1.36 per share Price / Cash Flow39.23 Book Value$15.44 per share Price / Book3.46Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$66.86 million Net Margins23.09% Return on Equity11.74% Return on Assets9.62%Miscellaneous Employees188 Outstanding Shares60,846,000Market Cap$3.25 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive CRSP News and Ratings via Email Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CRSP Rates by TradingView Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions What is Crispr Therapeutics' stock symbol? Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." How were Crispr Therapeutics' earnings last quarter? Crispr Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Wednesday, February, 12th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $1.19. The company had revenue of $77 million for the quarter, compared to analysts' expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. Crispr Therapeutics's revenue was up 76900.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.92) EPS. View Crispr Therapeutics' Earnings History. When is Crispr Therapeutics' next earnings date? Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Crispr Therapeutics. What price target have analysts set for CRSP? 14 analysts have issued 12-month price targets for Crispr Therapeutics' stock. Their forecasts range from $59.00 to $104.00. On average, they anticipate Crispr Therapeutics' share price to reach $80.41 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics. What is the consensus analysts' recommendation for Crispr Therapeutics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics. What are Wall Street analysts saying about Crispr Therapeutics stock? Here are some recent quotes from research analysts about Crispr Therapeutics stock: 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (2/17/2020) 2. Needham & Company LLC analysts commented, "Crispr reported 1Q19 financial results yesterday and we spoke w/ mgmt for an update. The company announced last night that regulatory agencies in both the U.S. and Canada have cleared initiation of a Phase 1/2 trial of CTX-110, an allogeneic CAR-T cell therapy in development for CD-19 cancers. Mgmt reiterated guidance for trial initiation in 2Q19. 1/2 trials of CTX-001 continue to enroll pts, although infusion of first pt in latter trial is not expected until mid-2019. Mgmt still aspires to present data from the CTX-001 program at the ASH mtg in Dec 2019, depending on trial progress. Reiterate BUY. Progression of CRISPR-based allogeneic CAR-T program into the clinic later in 2Q19 represents important milestone for the company." (5/1/2019) 3. William Blair analysts commented, "CRISPR Therapeutics AG We are initiating coverage on CRISPR Perform rating and $39 fair value estimate. While we acknowledge the innovative nature of the CRISPR/Cas9 discovery and the ease of use and flexibility of the platform as a potential ex vivo and in vivo therapeutic modality, we view the most-progressed indications being targeted—beta-thalassemia and sickle cell with CTX001 in col- laboration with Vertex and allogeneic T-cell therapy for hematological malignancies (acute lymphocytic leukemia [ALL], non-Hodgkin lymphoma [NHL], and multiple myeloma [MM])—as hyper-competitive spaces where the company is behind the leaders in clinical development." (3/13/2019) Has Crispr Therapeutics been receiving favorable news coverage? News articles about CRSP stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Crispr Therapeutics earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Crispr Therapeutics. Are investors shorting Crispr Therapeutics? Crispr Therapeutics saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 3,090,000 shares, a drop of 5.8% from the January 30th total of 3,280,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is presently 2.6 days. Currently, 8.3% of the shares of the company are short sold. View Crispr Therapeutics' Current Options Chain. Who are some of Crispr Therapeutics' key competitors? Some companies that are related to Crispr Therapeutics include Moderna (MRNA), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BioNTech (BNTX), BIO-TECHNE (TECH), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT) and Allogene Therapeutics (ALLO). What other stocks do shareholders of Crispr Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Shopify (SHOP), Intel (INTC) and Netflix (NFLX). Who are Crispr Therapeutics' key executives? Crispr Therapeutics' management team includes the folowing people: Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)Dr. Samarth Kulkarni, CEO & Director (Age 40)Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)Dr. Tony W. Ho, Head of R&D and Exec. VPDr. N. Anthony Coles Jr., Sr. Advisor (Age 59) When did Crispr Therapeutics IPO? (CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Crispr Therapeutics' major shareholders? Crispr Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (7.62%), Nikko Asset Management Americas Inc. (5.52%), ARK Investment Management LLC (5.36%), FMR LLC (1.73%), Credit Suisse AG (1.31%) and Abingworth LLP (0.94%). Company insiders that own Crispr Therapeutics stock include Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics. Which institutional investors are selling Crispr Therapeutics stock? CRSP stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Abingworth LLP, Lord Abbett & CO. LLC, Bank of America Corp DE, Versant Venture Management LLC, SG Americas Securities LLC, Barclays PLC and Credit Suisse AG. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak and Samarth Kulkarni. View Insider Buying and Selling for Crispr Therapeutics. Which institutional investors are buying Crispr Therapeutics stock? CRSP stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Nikko Asset Management Americas Inc., Capital International Investors, ARK Investment Management LLC, Laurion Capital Management LP, Columbus Circle Investors and Hodges Capital Management Inc.. View Insider Buying and Selling for Crispr Therapeutics. How do I buy shares of Crispr Therapeutics? Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Crispr Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $53.45. How big of a company is Crispr Therapeutics? Crispr Therapeutics has a market capitalization of $3.25 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.View Additional Information About Crispr Therapeutics. What is Crispr Therapeutics' official website? The official website for Crispr Therapeutics is http://www.crisprtx.com/. How can I contact Crispr Therapeutics? Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected] MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 319 (Vote Outperform)Underperform Votes: 308 (Vote Underperform)Total Votes: 627MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/29/2020 by MarketBeat.com StaffFeatured Article: What is the Dividend Aristocrat Index?
